Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DLMAF

Go back to Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
(NASDAQ: FULC) Delayed: 3.45 -0.1 (2.82%)
Previous Close $3.55    52 Week High $ 
Open $3.56    52 Week Low $ 
Day High $3.61    P/E N/A 
Day Low $3.43    EPS $ 
Volume 1,344,486